Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.

New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.

The findings from a double blinded randomized a Phase IIb/IIIa study combining nimotuzumab with gemcitabine in 192 patients with locally advanced or metastatic pancreatic cancer patients was recently published in the Annals of Oncology (Issue 10, 1 Oct 2017).

A total of 192 patients were randomly assigned to receive either nimotuzumab plus gemcitabine, or gemcitabine alone, with 1-year overall survival rates of 34% versus 19%, and median overall survival durations of 8.6 months versus 6.0 months, respectively (HR = 0.69; P = 0.03). The median progression free survival duration was 5.3 months in the experimental arm versus 3.5 months in the control arm (HR = 0.68; P = 0.02).

In a sub-group analysis, patients with pancreatic cancer and KRAS-wild-type disease who received nimotuzumab had significantly longer overall survival than those with pancreatic cancer KRAS-mutant disease (11.6 months versus 5.6 months; P = 0.03).

The randomized study showed that nimotuzumab in combination with gemcitabine is safe and well tolerated. The 1-year overall survival and progression free survival rates for the entire population were significantly improved. The study met its primary objectives.

To access the full publication please visit: https://academic.oup.com/annonc/article-abstract/28/10/2429/3926574?redirectedFrom=fulltext

Study ID: OSAG-101-PCS-07